奥西默替尼
医学
中止
化疗
肿瘤科
肺癌
内科学
酪氨酸激酶抑制剂
癌症
表皮生长因子受体
埃罗替尼
作者
Juan Bautista Blaquier,Gonzalo Recondo
标识
DOI:10.1080/1120009x.2022.2067705
摘要
Chemotherapy or involvement in a clinical trial remain the standard treatment for patients with EGFR mutant non-small cell lung cancer who have disease progression while receiving Osimertinib. Rapid progression, also known as flare-phenomenon, has been described after discontinuation of tyrosine kinase inhibitors. In this case, we describe a young woman who has extracranial progressive disease due to EGFR C797S resistance mutation while being treated with osimertinib, with a rapid neurological deterioration after osimertinib withdrawal due to flare-phenomenon progression in the brain, and a prompt intracranial response with osimertinib reintroduction in addition to chemotherapy to achieve extracranial diseases control.
科研通智能强力驱动
Strongly Powered by AbleSci AI